High-Purity Reagents for ATTR Amyloidosis Therapeutics: Stabilizers, Silencers, and Clearance Modality Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TTR drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | TTR (Prealbumin) Recombinant Protein HEK293 Expressed, High Purity (>95%), Endotoxin <1EU/µg. Sequence Verified. |
View TTR Products |
| Antigen (Pathogenic Mutants) | TTR V30M / V122I / T60A / L55P Mutant Proteins Hereditary ATTR variants for stabilizer screening. Sequence verified, theoretical MW confirmed. |
View TTR V30M Products |
| Gene Delivery | TTR Promise-ORF Lentivirus Full-length ORF for stable cell lines (e.g., HepG2 secretion models). |
View TTR Products |
| Benchmark Ab | Anti-TTR (Conformation-Specific) Recombinant Antibody Positive control for monomer vs. tetramer discrimination (Western/ELISA). |
View TTR Products |
| Validator | TTR siRNA Set For knockdown verification in hepatic models (specificity controls). |
View TTR Products |
| Complex Partner | RBP4 (Retinol Binding Protein 4) Holo-RBP4 complex formation for native conformation assays. |
View RBP4 Products |
| Clearance Pathway | LRP1 (LDL Receptor Related Protein 1) TTR clearance receptor for uptake mechanism studies. |
View LRP1 Products |
| Fc Receptor | FCGR3A (CD16a) Critical for ADCP (macrophage phagocytosis) activity assessment of amyloid-depleting antibodies. |
View FCGR3A Products |
| Plasma Reference | Albumin Major plasma protein; reference for PK/PD and competitive binding studies. |
View Albumin Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| TTR Stabilizer Screening (small molecule binding affinity) | Human WT & Pathogenic Mutant proteins (V30M, V122I) with >95% purity; suitable for ANS fluorescence displacement and thermal shift assays. |
| Amyloid Fibril Formation Kinetics | Endotoxin-controlled (<1EU/µg) proteins prevent LPS contamination artifacts in Thioflavin T aggregation assays. |
| Cross-species PK/PD Evaluation | Human, Mouse, Cynomolgus TTR orthologs with sequence verification for preclinical translation. |
| Monomer vs. Aggregate Specificity | Conformation-specific Benchmark Antibodies for native vs. misfolded TTR discrimination. |
| Hereditary ATTR (hATTR) Screening | Clinical mutants (V30M, V122I, T60A, L55P) available with strict sequence verification and theoretical MW confirmation. |
| Lack of Positive Controls for Depleting mAbs | Recombinant benchmark antibodies sequence-verified against advanced clinical assets. |
| False Positives in Gene Silencing Assays | Sequence-optimized siRNA sets for robust specificity checks in knockdown models. |
Live TTR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (TTR Amyloidosis)
- ➤ Latest Resistance & Mechanism Research
- ➤ Recent Patent Filings (Stabilizers & Silencers)
Global Clinical Landscape & Future Outlook
The therapeutic paradigm for Transthyretin Amyloidosis (ATTR) has shifted from supportive care to disease-modifying interventions. First-generation stabilizers (Tafamidis) have established the market, while RNA interference (Patisiran, Vutrisiran) and antisense oligonucleotides (Eplontersen) dominate the current pipeline. As second-generation CRISPR-based gene editors (NTLA-2001) and amyloid-clearing antibodies (NNC601-0001) advance into Phase 3, the R&D focus is pivoting toward combination strategies and tissue-specific depletion mechanisms. The race for TTR therapeutics is intensifying, with major players shifting focus from monomer stabilization to selective amyloid clearance and permanent gene silencing. As first-generation therapies reach peak penetration, the next wave of R&D targets amyloid fibril depletion and tissue-specific regeneration.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TTR Stabilizers (Small Molecule) | Pfizer (Vyndamax/Vyndaqel), BridgeBio (Acoramidis) | hATTR Cardiomyopathy, Polyneuropathy | Thermal Shift Assays (Need WT & Mutant TTR with accurate Tm) |
| siRNA / RNAi | Alnylam (Onpattro/Amvuttra) | hATTR Polyneuropathy, ATTR-CM | TTR Protein Level Quantification (Need high-sensitivity ELISA pairs) |
| ASO | Ionis/AstraZeneca (Wainua/Eplontersen) | hATTR Cardiomyopathy | Splice Variant Detection (Need ORF Lentivirus for mechanism studies) |
| Gene Editing (CRISPR) | Intellia (NTLA-2001), Regeneron | hATTR (Systemic), wtATTR | Genomic Integration Validation (Need TTR-specific antibodies for IHC) |
| Amyloid-Clearing mAb | Prothena/Novartis (NNC601-0001), Neurimmune/Alexion (NI006) | wtATTR Cardiomyopathy, Advanced ATTR | Aggregate-Specific Binding (Need fibrillar TTR vs. Monomer discrimination) |
Future Directions & Cross-sell Strategy
Combination therapy — "Silencer + Depleter" — is expected to become the standard for advanced ATTR patients. TarMart supports all modalities with high-purity reagents, conformation-defined antigens, and critical antibodies for preclinical validation. Related targets RBP4, LRP1, and FCGR3A enable comprehensive pathway studies.